BioVaxys Technology Corp. has announced a non-brokered private placement offering to raise up to $1.6 million, aimed at advancing innovative immunotherapy research.

BioVaxys Technology Corp. announces amendments to the Asset Purchase Agreement with Horizon Technology Finance Corp, enhancing their acquisition strategy and financial milestones.

BioVaxys Technology Corp. presents an update on its strategic initiatives, pipeline developments, and partnerships aimed at advancing innovative therapies for cancer and other diseases.

BioVaxys Technology Corp. announces an extension to the closing date for its non-brokered private placement, aimed at boosting investor participation.

BioVaxys Technology Corp. is setting its sights on revolutionizing mRNA vaccine delivery with its DPX™ platform, poised for substantial market growth by 2030.

BioVaxys Technology Corp. successfully closes its third tranche of a private placement, raising $537,500. The funds are designated for working capital and strategic initiatives.

BioVaxys Technology Corp. has announced the completion of its second tranche in a private placement, securing $175,000 to further its mission in biopharmaceutical innovation.

BioVaxys Technology Corp. has secured a significant supply of GMP-grade lipids to advance its DPX-based vaccine development, aiming for clinical trials.

BioVaxys Technology Corp. presented promising new data regarding its DPX immune educating platform, highlighting its effectiveness in cancer vaccines.